RLAY
Relay Therapeutics Inc
NASDAQ: RLAY · HEALTHCARE · BIOTECHNOLOGY
$12.57
-3.53% today
Updated 2026-04-29
Market cap
$2.41B
P/E ratio
—
P/S ratio
156.64x
EPS (TTM)
$-1.61
Dividend yield
—
52W range
$3 – $17
Volume
3.0M
Relay Therapeutics Inc (RLAY) Financial statements
SEC filings — annual and quarterly data.
Cash flow — annual
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $-44.13M | $-66.13M | $-102.49M | $-74.41M | $-229.49M | $-300.32M | $-249.11M | $-235.46M |
| Capital expenditures | $1.69M | $8.00M | $1.93M | $3.47M | $9.06M | $4.13M | $2.02M | $410000.00 |
| Depreciation | $2.15M | $2.85M | $3.55M | $3.92M | $4.13M | $5.27M | $5.46M | — |
| Stock-based comp | $2.89M | $4.46M | $31.96M | $48.45M | $56.14M | $86.03M | $94.14M | $62.42M |
| Free cash flow | $-45.82M | $-74.14M | $-104.42M | $-77.88M | $-238.55M | $-304.44M | $-251.13M | $-235.87M |
| Investing cash flow | $-1.68M | $-319.02M | $81.67M | $-479.51M | $-188.75M | $257.63M | $-41.08M | — |
| Financing cash flow | $394.97M | $5.61M | $426.51M | $388.09M | $289.91M | $34.75M | $270.15M | — |
| Dividends paid | — | — | — | — | — | — | — | — |
| Share repurchases | — | — | — | — | — | — | — | — |
| Debt repayment | — | — | — | — | — | — | — | — |
| Net change in cash | — | — | $405.69M | $-165.83M | $-128.32M | — | — | — |